A system and method for producing minerals from divalent ion-containing brine stream includes rejecting sulfate from a divalent-ion rich reject stream in a first nanofiltration seawater reverse osmosis (NF-SWRO) unit, producing solid calcium sulfate dihydrate and a magnesium-rich brine stream in a first concentration unit, concentrating the magnesium-rich brine stream to a saturation point of sodium chloride in a second concentration unit, producing solid sodium chloride and a supernatant product stream in a first crystallizing unit, produce a concentrated magnesium-rich bittern stream from the supernatant product stream in a third concentration unit, and at least one of producing hydrated magnesium chloride from the concentrated magnesium-rich bittern stream in a second crystallizing unit and producing anhydrous magnesium chloride by prilling the concentrated magnesium-rich bitterns stream under a hydrogen chloride atmosphere in a dry air process unit.

A system and method for producing minerals from divalent ion-containing brine stream includes rejecting sulfate from a divalent-ion rich reject stream in a first nanofiltration seawater reverse osmosis (NF-SWRO) unit, producing solid calcium sulfate dihydrate and a magnesium-rich brine stream in a first concentration unit, concentrating the magnesium-rich brine stream to a saturation point of sodium chloride in a second concentration unit, producing solid sodium chloride and a supernatant product stream in a first crystallizing unit, produce a concentrated magnesium-rich bittern stream from the supernatant product stream in a third concentration unit, and at least one of producing hydrated magnesium chloride from the concentrated magnesium-rich bittern stream in a second crystallizing unit and producing anhydrous magnesium chloride by prilling the concentrated magnesium-rich bitterns stream under a hydrogen chloride atmosphere in a dry air process unit.

The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.

The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.

A process for the purification of diaminophenothiazinium compounds, and particularly of methylene blue, is described. The process provides for simple and effective purification by reduction of the post-synthesis or commercially available diaminophenothiazinium compound to form a reduced complex thereof. This can then be purified in a more straightforward manner than the original compound by, for example, recrystallization before being allowed to oxidise back to the diaminophenothiazinium compound.

A process for the purification of diaminophenothiazinium compounds, and particularly of methylene blue, is described. The process provides for simple and effective purification by reduction of the post-synthesis or commercially available diaminophenothiazinium compound to form a reduced complex thereof. This can then be purified in a more straightforward manner than the original compound by, for example, recrystallization before being allowed to oxidise back to the diaminophenothiazinium compound.

The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.

The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.

A method for crystallization of cannabinoids includes: providing a substantially pure cannabinoid isolate; dissolving the cannabinoid isolate in a crystallization solvent; removing solvent by evaporation until the solution reaches saturation; adding a seed crystal of said cannabinoid; maintaining a supersaturated solution throughout the recrystallization process by the continual evaporation of solvent throughout the crystallization process by incubating the solution under heat and/or vacuum and repeating this process until crystals of the desired size have been produced.

This invention relates to a process for separating components of skim milk, in particular to the extraction of milk proteins and lactose from skim milk powder. The method involves combining skim milk powder with water, raising the temperature of the resulting mixture followed by cooling the mixture to produce a viscous casein fraction and a less viscous lactose fraction, and then separating the two fractions with optional purification.